PEPFAR HIV/AIDS response (United States and partner countries, 2003 to 2026)

Congress launched a multi-year U.S. program in 2003 to treat and prevent HIV abroad, which reports 26 million lives saved and over $130 billion in appropriations, while independent reviews found rules on prevention spending and speech that hurt field work, and a 2025 funding freeze and lapse in authority show how dependent partner countries remain.

The record

Origins and law

• The United States had funded global HIV work since 1986. PEPFAR (the President's Emergency Plan for AIDS Relief) was announced in January 2003 and authorized that year by the United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act, Public Law 108-25. (KFF fact sheet, updated May 2026; opened)
• The Act itself does not fix a $15 billion figure. The findings say the President asked Congress "to commit $15,000,000,000 over the next five years." Most programs are authorized at "such sums as may be necessary" for fiscal years 2004 to 2008. Up to $1 billion was authorized for the Global Fund in 2004, with U.S. contributions capped at 33 percent of all Global Fund funding. (Public Law 108-25, govinfo; opened, first 100,000 of about 138,000 characters read)
• The Act created a Coordinator of U.S. Government Activities to Combat HIV/AIDS Globally at the State Department, appointed with Senate consent. (P.L. 108-25, Section 102)
• Reauthorizations: Lantos-Hyde Act (2008), PEPFAR Stewardship Act (2013), PEPFAR Extension Act (2018), and a short extension in March 2024 that ran to March 25, 2025. Eight time-bound provisions have lapsed since. KFF says PEPFAR remains part of permanent law and continues as long as Congress funds it. (KFF)

Timeline

Funding and reported results

• KFF says appropriations total over $130 billion, from $1.9 billion in FY 2004 to $6 billion in FY 2026. (KFF)
• PEPFAR reports an estimated 26 million lives saved (KFF) or "more than 25 million" (State Department results page). As of September 30, 2023 it supported 20.47 million people on antiretroviral treatment and about 5.5 million babies born HIV-free to mothers living with HIV (State Department). For FY 2024 KFF reports 83.8 million people tested, 20.6 million on treatment and 7.8 million babies born without HIV. (State Department archived results page; opened)
• KFF cites UNAIDS 2024 figures: about 40.8 million people living with HIV, 1.3 million new infections, 630,000 AIDS-related deaths, 31.6 million on treatment. It notes that the "26 million lives saved" figure is PEPFAR's own estimate and not a UNAIDS figure. (KFF)

Disputed numbers

| Item | Figure A | Figure B | Notes | |---|---|---| | Lives saved | More than 25 million (State Dept archived page, referring to about 20 years) | 26 million (KFF, May 2026, "PEPFAR reports") | Both from PEPFAR reporting; modeled, different dates | | Babies born HIV-free | 5.5 million (State Dept, through Sept. 2023) | 7.8 million (KFF, FY 2024) | The two sources likely use different definitions or years; not reconciled | | People on treatment | 20.47 million (Sept. 30, 2023) | 20.6 million (FY 2024) | Different years | | Early mortality effect | 740,000 lives saved in 9 countries, 2004 to 2008 (Bendavid et al., JAMA 2012) | No significant difference in 13 of 14 health indicators between focus and non-focus countries (Duber et al., 2010, as described in a replication proposal) | Different country sets (27 vs 46) and years (2004 to 2008 vs 2000 and 2006) |

Independent evidence

• A 2012 JAMA study by Eran Bendavid, Charles Holmes, Jay Bhattacharya and Grant Miller used survey data on 1.5 million adults in 27 African countries. It found the odds of death from any cause were 16 to 20 percent lower in the nine PEPFAR focus countries from 2004 to 2008, and estimated more than 740,000 lives saved. Holmes was PEPFAR's chief medical officer and supplied country data. The authors describe associations, not proof PEPFAR alone caused the decline. (Stanford Medicine news release, May 2012; opened. The JAMA paper itself was not opened.)
• A replication proposal to 3ie by Jiangtao Luo (University of Nebraska Medical Center) restates the original's limits: it could not separate all-cause from HIV mortality, and it found no detectable difference by PEPFAR intensity across districts in Tanzania and Rwanda. It also cites the Duber 2010 comparison finding. This document is a proposal, not results. (3ie replication proposal; opened)
• The 2013 Institute of Medicine evaluation judged PEPFAR to have "played a transformative role" and said "its work is unfinished." It found gaps in linking testing to care, retention and adherence; said PEPFAR "lacks clear objectives for outcomes across all types of prevention interventions"; noted barriers for men who have sex with men, sex workers and people who inject drugs, and restrictive legal environments; and warned many partner countries depend heavily on U.S. or Global Fund money. It said transition "cannot be achieved on a prescribed generic timeline." (National Academies, Evaluation of PEPFAR, summary; opened)

Costs, harms and implementation problems

• Abstinence earmark. Starting in fiscal year 2006, the Act required 33 percent of prevention funds to go to abstinence-until-marriage programs. GAO found this made it difficult for country teams to build integrated local prevention. Reporting on the GAO findings says some mother-to-child transmission services were cut to meet the target, and NGOs were unsure how to separate condom information from condom promotion. (GAO-06-395, Apr. 4, 2006; aidsmap; both opened) Lantos-Hyde removed the requirement in 2008. A 2013 journal article reports abstinence and faithfulness spending fell from 34.5 percent of the prevention budget in 2008 to 16.1 percent in 2011 (via a resource list on PubMed Central; the article itself was not read). (PMC3984004; opened)
• Anti-prostitution pledge. P.L. 108-25 Section 301(f) barred aid to groups lacking a policy explicitly opposing prostitution and sex trafficking. On June 20, 2013 the Supreme Court held 6 to 2 (Kagan recused; Scalia and Thomas dissenting) in Agency for International Development v. Alliance for Open Society International (No. 12-10) that the pledge violated the First Amendment as applied to U.S. organizations. (P.L. 108-25; KFF; opened)
• Concentration of money. A 2008 dataset analyzed by the Center for Global Development found about 477 contractors received roughly $3.56 billion, with about 58 percent going to 25 contractors, nearly all U.S.-based; developing-country governments as prime partners got about $301 million. The authors also raised workforce and parallel-system concerns. (CGD blog, Feb. 2013; opened. This is a think-tank blog written before the IOM report.)
• 2025 disruption. KFF reports a foreign aid review and freeze limited PEPFAR to a waiver for "life-saving HIV services," not all of which have continued; DREAMS (a program for adolescent girls and young women) was discontinued; USAID was dissolved with global health folded into the State Department; no Global AIDS Coordinator has been nominated. Data for the last quarter of FY 2025 show treatment totals stable but new enrollments, testing and PrEP use "dropped significantly." (KFF)
• Transition plan. The September 2025 strategy says the U.S. will fund 100 percent of current commodity and frontline worker costs in 2026, with reduced funding afterward, and integrate HIV services into country health systems. (KFF)

What this case shows

1. A public number, a public vote, a public yearly bill. The goal was stated by the President, voted by Congress and funded in appropriations that anyone can read. The KFF table of yearly funding, from $1.9 billion to $6 billion, is the kind of record a citizen can follow. (KFF; P.L. 108-25)
2. The headline results are modeled and self-reported. "26 million lives saved" is PEPFAR's own estimate, not UNAIDS's. An outside study found a signal in 2004 to 2008, another comparison found none on most indicators. People can vote on a program only if they are told which number is a count and which is a model. (KFF; Stanford; 3ie)
3. Rules written in Washington changed what happened in clinics. A prevention spending share and a speech pledge shaped field work for years before GAO and the Supreme Court weighed in. Those who were most affected, patients and local groups, had no vote on them. (GAO-06-395; KFF on the 2013 ruling)
4. Some people were left out by design or by law. The IOM found barriers for men who have sex with men, sex workers and people who inject drugs, plus restrictive legal settings. The pledge conditioned aid on a stated position about sex work. (IOM summary; P.L. 108-25)
5. Dependence is the open ledger. The IOM warned of fragility in 2013. In 2025, a freeze and a lapse in authority tested it, and enrollments and testing fell. Voters in donor countries and patients in partner countries bear different risks from the same decision. (IOM; KFF)

The strongest objections, and our answers

1. Objection: The program is the largest single-disease effort in history and the numbers prove it. Mitigation: We report the numbers, including 20.6 million on treatment, and the outside study with a 16 to 20 percent lower adult mortality. We label them modeled or associational and cite the comparison that found no difference on most indicators.
2. Objection: The abstinence rule reflected a legitimate moral and public health view. Supporters argued it promoted behavior change, and the Act listed abstinence and fidelity with condoms. Mitigation: The Act endorsed a combined approach, and GAO's finding was about operations: it made integrated local programs hard. We do not rule on the merits of abstinence education. A 2013 article cited in a resource list says evidence for abstinence-until-marriage programs was limited, but we did not read it directly.
3. Objection: The 2025 problems are due to politics, not to PEPFAR's design. Mitigation: We do not assign cause to any party. The KFF record states the facts: a freeze, a waiver, a lapse. The IOM warned about dependence in 2013, which is a design question separate from any one administration.
4. Objection: Contractor concentration is a 2008 figure and may be out of date. Mitigation: Correct. It is one dataset from one year, from a think-tank blog. We flag it and make no claim about later years.
5. Objection: Using State Department and KFF figures repeats PEPFAR's own claims. Mitigation: We give each figure with its source, mark which are self-reported, and add outside evidence (JAMA via Stanford release, IOM, GAO, the Court).

Open questions: what would change our minds

• The JAMA 2012 paper, the Duber 2010 paper and the 2013 Abstinence Promotion article were not opened directly; we used a news release, a replication proposal and a resource list. Unverified.
• No completed replication result was found. The 3ie item is a proposal.
• The statute's 33 percent abstinence language and Global Fund details are from GAO and the Act's first 100,000 characters; the section that sets the abstinence rule was not read in the Act itself. The portion of the Act past 100,000 characters was not read.
• How UNAIDS or independent modelers estimate lives saved by PEPFAR versus all donors was not found. The State Department and KFF figures are PEPFAR's own.
• The "7.8 million" versus "5.5 million" babies-born-HIV-free gap is unreconciled.
• Total real-dollar cost per life saved and the share of money going to U.S. versus local organizations since 2008 were not found.
• The effect of the 2025 freeze on deaths or infections was not found in a peer-reviewed source; KFF reports program data only.
• The 2013 IOM recommendations on cost and on key populations in the full report were not read beyond the summary chapter.
• Congressional Research Service reports could not be opened (the site blocks automated fetching).

Sources

Found an error or a better source? We keep every correction on the record with its date and reason. Nothing here is quietly rewritten.